Trial · NCT07297290
Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
NCT07297290, Phase 3, Recruiting, University Of Nigeria Teaching Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI). Trials, record NCT07297290. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07297290
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Metformin Use on Weight Loss in Obese, Non-diabetic People (MOWRI)
- NCT number
- NCT07297290
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 220 participants, estimated
- Lead sponsor
- University Of Nigeria Teaching Hospital
- Conditions
- Obesity and Cardiovascular Risk, Insulin Resistance, Obesity (Body Mass Index >30 kg/m2)
- Interventions
- Metformin, Placebo
- First posted
- 2025-12-22
- Last updated
- 2025-12-22
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of Metformin on body weight change | 24 months | Determine percent change in body weight in kilograms and height in meters which will be combined to report BMI in kg/m2 among the treatment arm and compared to the control arm. |
| Primary | Effect of Metformin on Cardiovascular risk | 24 months | Determine percent change in the 10 year Framingham risk score for cardiovascular disease among the treatment arm and compare with the control arm. |
| Primary | Effect of Metformin on insulin resistance in non-diabetics | 24 months | Determine percent change in the insulin resistance indices using Homeostatic model assessment (HOMA) among the treatment arm and compare to the control arm. |
| Primary | Effect of metformin on waist circumference change | 24 months | Determine the percent change in waist circumference measured in cm at baseline and final readings among the treatment arm and compared to the control arm. |
| Primary | Effect of metformin on waist-to-hip circumference change | 24 months | Determine the percent change in waist circumference measured in cm, and hip circumference measured in cm, which will be combined to report waist-to-hip circumference ratio change among the treatment arm and compared to the control arm. |
| Secondary | Safety of Metformin extended release tablet taken daily | 24 months | Determine the incidence of adverse effects at grade 3 or higher level using the Adverse Effect questionnaire when dosage of less than or equal to 1500mg of Metformin X extended release tablet is taken daily. |
| Secondary | Percent drug compliance to Metformin extended release taken once daily. | 24 months | Determine the percent drug compliance to administered Metformin extended release tablets, determined by count of actual number of drug tablets administered over count of what was expected to have been administered, expressed as a percentage. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07297290
GET https://conductscience.org/api/trials/v1/NCT07297290/registered